Table 1.
The percentage of CD25–, CD25low and CD25high CD4+ T cells expressing different activation and differentiation markers (median with 25 and 75 percentiles)
| CD25– | CD25low | CD25high | |
|---|---|---|---|
| Highest in CD25high | |||
| CD71 | 6·3% (4·7–8·4) | 14% (8·4–19) | 27% (23–32) |
| CD122 | 1·1% (0·9–2·2) | 2·1% (1·2–3·2) | 7·3% (5·6–8·6) |
| HLA-DR | 5·8% (5·2–7·8) | 8·3% (5·1–10·2) | 32% (25–37) |
| CCR4 | 18% (15–22) | 43% (31–53) | 67% (62–70%) |
| CCR5 | 4·3% (3·0–6·5) | 8·6% (6·8–14) | 14% (11–23) |
| CD103 | 0·9% (0·5–1·1) | 2·4% (1·6–3·4) | 5·3% (3·2–6·8) |
| Surface CTLA-4 | 4·7% (3·1–6·3) | 7·5% (5·8–10·3) | 10% (7·9–14) |
| Intracellular and surface CTLA-4 | 1·2% (0·9–2·6) | 2·9% (1·9–5·9) | 6·2% (3·7–17) |
| GITR | 3·9% (3·2–5·0) | 9·9% (7·7–13) | 14% (11–17%) |
| CD137 | 1·1% (0·8–1·4) | 2·5% (2·0–3·9) | 15% (9·7–18) |
| Lowest in CD25high | |||
| CCR7 | 86% (74–91) | 60% (51–77) | 51% (37–66) |
| CD49dhigh | 31% (23–36) | 41% (33–47%) | 19% (15–22) |
| Highest in CD25low and CD25high | |||
| PD-1 | 2·6% (2·1–4·6) | 4·7% (3·4–7·1) | 4·7% (2·7–8·1) |
| CD134 | 0·5% (0·4–0·9) | 2·8% (2·0–3·9) | 3·3% (2·4–5·8) |
| Highest in CD25– and CD25high | |||
| CD62L | 95% (92–96) | 77% (69–89) | 94% (88–95) |
CTLA-4: cytotoxic T lymphocyte antigen-4; GITR: glucocorticoid-induced tumour necrosis factor receptor family-related; HLA-DR: human leucocyte antigen DR.